| 產(chǎn)品編號(hào) | BIO0975SM |
| 英文名稱 | Anti-IL-13 & IL-4 Reference Antibody (romilkimab Biosimilar) |
| 別 名 | IL-13 & IL-4; romilkimab |
| 抗體來源 | |
| 克隆類型 | Monoclonal |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 198.12kDa |
| 性 狀 | Lyophilized |
| 亞 型 | DVD-Ig |
| 純化方法 | Protein A |
| 緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
| 保存條件 | -80°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Romilkimab bound to IL-3 protein, and then rebounded to secondary antibodies(Anti-6*his-HRP ) , and read OD450. As shown in fig, Romilkimab bound to Human IL-3-His, and the EC50 was 0.088 nM.
Romilkimab bound to IL-4 protein, and then rebounded to secondary antibodies(Anti-Human-κ+λ-HRP) , and read OD450. As shown in fig, Romilkimab bound to Human IL-4-Fc, and the EC50 was 0.040 nM.
The purity of Anti-IL-13 & IL-4 Reference Antibody (romilkimab) is 97.45%, determined by SEC-HPLC.
Anti-IL-13 & IL-4 Reference Antibody (romilkimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The detected molecular weight of Anti-IL-13 & IL-4 Reference Antibody (Romilkimab) is 197.87 kDa.
|
